Co-Authors
This is a "connection" page, showing publications co-authored by SIQING FU and WEI HU.
Connection Strength
1.068
-
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41.
Score: 0.445
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.098
-
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9.
Score: 0.086
-
Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov; 3(3):162-77.
Score: 0.086
-
Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):325-38.
Score: 0.076
-
Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32.
Score: 0.074
-
Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85.
Score: 0.071
-
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.
Score: 0.030
-
Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009 Oct; 201(4):367.e1-6.
Score: 0.022
-
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82.
Score: 0.021
-
Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):600-14.
Score: 0.020
-
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80.
Score: 0.019
-
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):739-63.
Score: 0.019